[6-碘-2-甲基-1-[2-(4-吗啉基)乙基]-1H-吲哚-3-基](4-甲氧基苯基)甲酮结构式
|
常用名 | [6-碘-2-甲基-1-[2-(4-吗啉基)乙基]-1H-吲哚-3-基](4-甲氧基苯基)甲酮 | 英文名 | AM630 |
---|---|---|---|---|
CAS号 | 164178-33-0 | 分子量 | 504.361 | |
密度 | 1.5±0.1 g/cm3 | 沸点 | 605.9±55.0 °C at 760 mmHg | |
分子式 | C23H25IN2O3 | 熔点 | N/A | |
MSDS | 中文版 美版 | 闪点 | 320.3±31.5 °C | |
符号 |
GHS09 |
信号词 | Warning |
用途6-Iodopravadoline (AM630) 是一种选择性的 CB2 拮抗剂,Ki 值为 31.2 nM,对其选择性是对 CB1 受体的 165 倍。 |
中文名 | [6-碘-2-甲基-1-[2-(4-吗啉基)乙基]-1H-吲哚-3-基](4-甲氧基苯基)甲酮 |
---|---|
英文名 | (6-Iodo-2-methyl-1-(2-morpholinoethyl)-1H-indol-3-yl)(4-methoxyphenyl)methanone |
中文别名 | (6-碘-2-甲基-1-(2-吗啉-4-基乙基)-1H-吲哚-3-基)(4-甲氧基苯基)甲酮 |
英文别名 | 更多 |
描述 | 6-Iodopravadoline (AM630) 是一种选择性的 CB2 拮抗剂,Ki 值为 31.2 nM,对其选择性是对 CB1 受体的 165 倍。 |
---|---|
相关类别 | |
靶点 |
Ki: 31.2 nM (CB2) |
参考文献 |
密度 | 1.5±0.1 g/cm3 |
---|---|
沸点 | 605.9±55.0 °C at 760 mmHg |
分子式 | C23H25IN2O3 |
分子量 | 504.361 |
闪点 | 320.3±31.5 °C |
精确质量 | 504.090973 |
PSA | 43.70000 |
LogP | 4.65 |
外观性状 | 灰白色固体 |
蒸汽压 | 0.0±1.7 mmHg at 25°C |
折射率 | 1.647 |
储存条件 | 2-8°C |
计算化学 | 1.疏水参数计算参考值(XlogP):4 2.氢键供体数量:0 3.氢键受体数量:4 4.可旋转化学键数量:6 5.互变异构体数量:无 6.拓扑分子极性表面积43.7 7.重原子数量:29 8.表面电荷:0 9.复杂度:548 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
Lack of presynaptic interaction between glucocorticoid and CB1 cannabinoid receptors in GABA- and glutamatergic terminals in the frontal cortex of laboratory rodents.
Neurochem. Int. 90 , 72-84, (2015) Corticosteroid and endocannabinoid actions converge on prefrontocortical circuits associated with neuropsychiatric illnesses. Corticosteroids can also modulate forebrain synapses by using endocannabin... |
|
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
Carcinogenesis 35(12) , 2787-97, (2014) Cannabigerol (CBG) is a safe non-psychotropic Cannabis-derived cannabinoid (CB), which interacts with specific targets involved in carcinogenesis. Specifically, CBG potently blocks transient receptor ... |
|
A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis.
Br. J. Pharmacol. 172 , 3579-95, (2015) Sativex(®) is an oromucosal spray, containing equivalent amounts of Δ(9) -tetrahydrocannabinol (Δ(9) -THC) and cannabidiol (CBD)-botanical drug substance (BDS), which has been approved for the treatme... |
{6-Iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl}(4-methoxyphenyl)methanone |
[6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]-(4-methoxyphenyl)methanone |
{6-Iodo-2-methyl-1-[2-(morpholin-4-yl)ethyl]-1H-indol-3-yl}(4-methoxyphenyl)methanone |
AM-630 |
Methanone, [6-iodo-2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)- |
AM630 |